<DOC>
	<DOCNO>NCT02806050</DOCNO>
	<brief_summary>The purpose evaluate whether non invasive vivo image estrogen receptor ( ER ) presence metastatic breast cancer patient mean 18F-fluoro-estradiol ( FES ) positron emission tomography ( PET ) use predict treatment response palbociclib plus letrozole . As ER expression predict response palbociclib metastatic breast cancer patient investigator hypothesize lesion low uptake FES-PET respond combination letrozole plus palbociclib .</brief_summary>
	<brief_title>Palbociclib FES PET</brief_title>
	<detailed_description>To evaluate feasibility study whether low uptake FES-PET baseline relate non response letrozole plus palbociclib treatment . The investigator perform feasibility study 15 patient metastatic breast cancer , eligible letrozole palbociclib therapy . All patient treat letrozole 2.5mg daily continuously throughout 28-day cycle . This combined palbociclib 125 mg daily 21 consecutive day follow 7 day treatment . At baseline patient FES PET scan . Currently combination palbociclib letrozole approve FDA initial endocrine-based therapy postmenopausal woman ER positive HER2 negative advance breast cancer . This base improved progression free survival 10 month compare endocrine therapy alone first second line hormonal treatment ER-positive metastatic breast cancer . In Europe , approval expect late 2016 . Therefore , study , patient receive ( presumably effective ) treatment combination , patient standard access Netherlands yet . In addition standard control visit clinic , two extra visit perform part study : screen FES-PET scan . In future , study may potentially contribute improved selection patient combination treatment . This relevance view optimal treatment individual patient , avoid unnecessary toxicity financial burden .</detailed_description>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>In order eligible participate study , subject must meet following criterion : 1 . Patients ER positive ( i.e . &gt; 1 % staining ) , HER2 negative metastatic breast cancer ( preferably assessment fresh metastasis biopsy , alternatively archival metastasis biopsy ) 2 . Postmenopausal status define : Age ≥60 year Previous bilateral oophorectomy Age &lt; 60 year amenorrhea &gt; 12 month absence interfere hormonal therapy ( LHRH agonists ERantagonists Age &lt; 60 year use ER antagonist amenorrhea &gt; 12 month FSH &gt; 24U/L LH &gt; 14U/L 3 . Adequate bone marrow organ function define follow : Absolute neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L White blood cell count &gt; 3 x 109/L AST ALT &lt; 3.0 x upper limit normal ( ULN ) &lt; 5 xULN case know liver metastasis . Alkaline phosphatase &lt; 2.5 x ULN Total serum bilirubin &lt; ULN total bilirubin &lt; 3.0 x ULN direct bilirubin within normal range patient Gilbert 's Syndrome Creatinine clearance &gt; 50mL/min Lipase/amylase &lt; 1/5 x ULN Prothrombin time , partial thromboplastin time INR &lt; 1.5 x ULN 4 . ECOG performance 02 5 . Signed write informed consent 6 . Able comply protocol 7 . Age ≥18 year A potential subject meet follow criterion exclude participation study : 1 . Life expectancy &lt; 3 month 2 . Evidence central nervous system metastases 3 . Presence lifethreatening visceral metastasis 4 . Prior use CDK4/6 inhibitor 5 . Use estrogen receptor ligands include estrogen , fulvestrant tamoxifen &lt; 6 week study entry . 6 . Use anticancer therapy &lt; 2 week prior start palbociclib 7 . Concurrent malignancy 8 . Active cardiac disease history cardiac dysfunction 9 . Patient currently receive follow medication discontinue 7 day prior start treatment know strong inducer inhibitor CYP3A4/5 , know risk prolong QT interval induce Torsades de Pointes , narrow therapeutic window predominantly metabolize CYP3A4/5 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FES PET</keyword>
	<keyword>Palbociclib</keyword>
</DOC>